Treatment of short stature and growth hormone deficiency in children with somatotropin (rDNA origin)

Treatment of short stature and growth hormone deficiency in children with somatotropin (rDNA origin)

Dana S HardinOhio State University and Columbus Children’s Hospital, Columbus, Ohio, USAAbstract: Somatotropin (growth hormone, GH) of recombinant DNA origin has provided a readily available and safe drug that has greatly improved management of children and adolescents with GH deficien...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Dana S Hardin
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2008
Materias:
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/1758e43d49e74764a952c0fea69fc65b
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:1758e43d49e74764a952c0fea69fc65b
record_format dspace
spelling oai:doaj.org-article:1758e43d49e74764a952c0fea69fc65b2021-12-02T06:55:52ZTreatment of short stature and growth hormone deficiency in children with somatotropin (rDNA origin)1177-54751177-5491https://doaj.org/article/1758e43d49e74764a952c0fea69fc65b2008-08-01T00:00:00Zhttp://www.dovepress.com/treatment-of-short-stature-and-growth-hormone-deficiency-in-children-w-a1924https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Dana S HardinOhio State University and Columbus Children’s Hospital, Columbus, Ohio, USAAbstract: Somatotropin (growth hormone, GH) of recombinant DNA origin has provided a readily available and safe drug that has greatly improved management of children and adolescents with GH deficiency (GHD) and other disorders of growth. In the US and Europe, regulatory agencies have given approval for the use of GH in children and adults who meet specific criteria. However, clinical and ethical controversies remain regarding the diagnosis of GHD, dosing of GH, duration of therapy and expected outcomes. Areas which also require consensus include management of pubertal patients, transitioning pediatric patients to adulthood, management of children with idiopathic short stature and the role of recombinant IGF-1 in treatment. Additionally, studies have demonstrated anabolic benefits of GH in children who have inflammatory-based underlying disease and efficacy of GH in overcoming growth delays in people treated chronically with corticosteroids. These areas are open for possible new uses of this drug. This review summarizes current indications for GH use in children and discusses areas of clinical debate and potential anabolic uses in chronic illness.Keywords: somatotropin, growth hormone deficiency, children, short stature Dana S HardinDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2008, Iss Issue 4, Pp 655-661 (2008)
institution DOAJ
collection DOAJ
language EN
topic Medicine (General)
R5-920
spellingShingle Medicine (General)
R5-920
Dana S Hardin
Treatment of short stature and growth hormone deficiency in children with somatotropin (rDNA origin)
description Dana S HardinOhio State University and Columbus Children’s Hospital, Columbus, Ohio, USAAbstract: Somatotropin (growth hormone, GH) of recombinant DNA origin has provided a readily available and safe drug that has greatly improved management of children and adolescents with GH deficiency (GHD) and other disorders of growth. In the US and Europe, regulatory agencies have given approval for the use of GH in children and adults who meet specific criteria. However, clinical and ethical controversies remain regarding the diagnosis of GHD, dosing of GH, duration of therapy and expected outcomes. Areas which also require consensus include management of pubertal patients, transitioning pediatric patients to adulthood, management of children with idiopathic short stature and the role of recombinant IGF-1 in treatment. Additionally, studies have demonstrated anabolic benefits of GH in children who have inflammatory-based underlying disease and efficacy of GH in overcoming growth delays in people treated chronically with corticosteroids. These areas are open for possible new uses of this drug. This review summarizes current indications for GH use in children and discusses areas of clinical debate and potential anabolic uses in chronic illness.Keywords: somatotropin, growth hormone deficiency, children, short stature
format article
author Dana S Hardin
author_facet Dana S Hardin
author_sort Dana S Hardin
title Treatment of short stature and growth hormone deficiency in children with somatotropin (rDNA origin)
title_short Treatment of short stature and growth hormone deficiency in children with somatotropin (rDNA origin)
title_full Treatment of short stature and growth hormone deficiency in children with somatotropin (rDNA origin)
title_fullStr Treatment of short stature and growth hormone deficiency in children with somatotropin (rDNA origin)
title_full_unstemmed Treatment of short stature and growth hormone deficiency in children with somatotropin (rDNA origin)
title_sort treatment of short stature and growth hormone deficiency in children with somatotropin (rdna origin)
publisher Dove Medical Press
publishDate 2008
url https://doaj.org/article/1758e43d49e74764a952c0fea69fc65b
work_keys_str_mv AT danashardin treatmentofshortstatureandgrowthhormonedeficiencyinchildrenwithsomatotropinrdnaorigin
_version_ 1718399674580205568

Ejemplares similares